Drew Dennison

Drew Dennison is the current CEO of AI Proteins and a board member of NextRNA Therapeutics. Drew has also held positions at Dynamic Cell Therapies, Inc., SimpleRose, Wugen, Geneoscopy, CareVet, Lightchain Capital LLC, and TD Ameritrade.

Dennison has played an integral role in several company integrations, most notably the integration between Scottrade, TD Ameritrade, and TD Bank. As the Integration Co-Lead and Executive Sponsor, they worked closely with the overall lead from TD Ameritrade to develop project plans, generate and adhere to financial projections, identify and manage risks, and execute against the integration schedule. Thanks to their efforts, the integration was completed seven months ahead of what was communicated to the analyst community - generating approximately $170 million in synergy acceleration and savings, and minimizing client retention risk in the interim operating model.

Drew Dennison is a proven leader with a track record of success in both startups and established companies. Drew is a strategic thinker who is able to see the big picture and develop creative solutions to complex problems. Drew is a strong communicator who is able to build consensus among stakeholders with competing interests. Drew is a results-oriented individual who is able to set ambitious goals and achieve them.

Drew Dennison is a Bachelor of Business Administration (BBA) from The University of Iowa Tippie College of Business. Drew also has a Graduate degree from the Securities Industry Institute's Executive Education Program at The Wharton School.

Some direct reports include Ben Meinen - Scientist, Andrea Armstrong - Chief People Officer, and Julia Novina - Chief Legal Officer.